Real-world experience of Quantiferon-CMV directed prophylaxis in lung transplant recipients.

Background: The Quantiferon-Cytomegalovirus (QF-CMV) assay was introduced to predict CMV infection and inform prophylaxis duration in our lung transplant recipients (LTR) from 2012. The aims of this retrospective cohort study were to review our QF-CMV experience, understand factors associated with positive results and further explore its predictive utility.

Methods: LTR with QF-CMV testing performed at 5 months post-transplant were included.